

Minkyu Jung

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1572101/minkyu-jung-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

1,234
citations

19
h-index

31
g-index

97
ext. papers

1,505
ext. citations

4.2
avg, IF

3.94
L-index

#	Paper	IF	Citations
92	Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 351-351	2.2	
91	Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 330-330	2.2	
90	Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. <i>Cancers</i> , 2022 , 14, 2659	6.6	2
89	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021 , 39, 1366-1374	4.3	2
88	Plasma Membrane Localized GCaMP-MS4A12 by Orai1 Co-Expression Shows Thapsigargin- and Ca-Dependent Fluorescence Increases. <i>Molecules and Cells</i> , 2021 , 44, 223-232	3.5	
87	Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. <i>Cancer Research and Treatment</i> , 2021 , 53, 323-329	5.2	6
86	Adverse Prognostic Impact of Postoperative Complications After Gastrectomy for Patients With Stage II/III Gastric Cancer: Analysis of Prospectively Collected Real-World Data. <i>Frontiers in Oncology</i> , 2021 , 11, 611510	5.3	1
85	RAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021 , 594, 418-423	50.4	20
84	Detection of asymptomatic recurrence improves survival of gastric cancer patients. <i>Cancer Medicine</i> , 2021 , 10, 3249-3260	4.8	0
83	Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4063-4063	2.2	0
82	Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators. <i>Frontiers in Oncology</i> , 2021 , 11, 659754	5.3	1
81	Abstract CT159: Open label, single-arm, multi-center phase Ib/II study to evaluate the safety and efficacy of nivolumab in combination with paclitaxel in Epstein-Barr virus (EBV)-related, or microsatellite instability-high (MSI-H), or programmed cell death ligand 1 (PD-L1) positive advanced gastric cancer (AGC) 2021.		2
80	Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative F-FDG PET/CT in patients with localized primary gastrointestinal stromal tumors. <i>Cancer & Metabolism</i> , 2021 , 9, 8	5.4	2
79	Phase Ib trial of varlitinib plus weekly paclitaxel in EGFR/HER2 co-expressing advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 227-227	2.2	1
78	A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 218-218	2.2	9
77	A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2020 , 19, e140-e150	3.8	3
76	Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3681-3681	2.2	13

75	Safety and preliminary antitumor activity of the transforming growth factor beta (TGF- β) receptor I kinase inhibitor, vactosertib, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16505-e16505	2.2	2
74	Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy. <i>Cancer Research and Treatment</i> , 2020 , 52, 730-738	5.2	4
73	Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020 , 18, 587-601	6.4	14
72	The Role of Primary Tumor Resection in Colorectal Cancer Patients with Asymptomatic, Synchronous, Unresectable Metastasis: A Multicenter Randomized Controlled Trial. <i>Cancers</i> , 2020 , 12,	6.6	14
71	Objectively measured physical activity during chemotherapy in colon cancer patients. <i>Supportive Care in Cancer</i> , 2020 , 28, 2597-2604	3.9	1
70	Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer 2019 , 7, 268		14
69	Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 1153-1163	14	
68	S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. <i>Cancer Research and Treatment</i> , 2019 , 51, 1-11	5.2	13
67	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , 2019 , 112, 20-28	7.5	0
66	Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. <i>Radiotherapy and Oncology</i> , 2019 , 140, 143-149	5.3	3
65	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , 2019 , 51, 819-831	5.2	8
64	Oxaliplatin-induced Peripheral Neuropathy, Symptoms, Distress and Quality of Life among Korean Patients with Gastrointestinal Cancer. <i>Asian Oncology Nursing</i> , 2019 , 19, 204	0.4	
63	Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors. <i>Journal of Cancer Prevention</i> , 2019 , 24, 48-53	3	
62	Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. <i>Gastric Cancer</i> , 2018 , 21, 802-810	7.6	7
61	Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). <i>Gastric Cancer</i> , 2018 , 21, 819-830	7.6	15
60	Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e513-e518	3.8	14
59	The prognostic value of volume-based parameters using F-FDG PET/CT in gastric cancer according to HER2 status. <i>Gastric Cancer</i> , 2018 , 21, 213-224	7.6	14
58	Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3222-3230	3.1	40

57	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial. <i>Clinical Cancer Research</i> , 2018 , 24, 5272-5281	12.9	13
56	Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma. <i>Cancer Research and Treatment</i> , 2018 , 50, 1238-1251	5.2	7
55	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. <i>BMC Cancer</i> , 2018 , 18, 1116	4.8	31
54	Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer. <i>Anticancer Research</i> , 2018 , 38, 6171-6180	2.3	7
53	ASO Author Reflections: Prognostic Impact of Body Composition Change After Gastrectomy for Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 765-766	3.1	
52	A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. <i>AAPS Journal</i> , 2018 , 20, 72	3.7	
51	Correlation between KRAS mutation and F-FDG uptake in stage IV colorectal cancer. <i>Abdominal Radiology</i> , 2017 , 42, 1621-1626	3	14
50	Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. <i>BMC Cancer</i> , 2017 , 17, 615	4.8	8
49	Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. <i>Oncotarget</i> , 2017 , 8, 61837-61845	6.1845	10
48	Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 227-235	3.1	28
47	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. <i>Oncotarget</i> , 2017 , 8, 31169-31179	3.3	8
46	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. <i>Oncotarget</i> , 2017 , 8, 38389-38398	3.38398	7
45	Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. <i>Cancer Research and Treatment</i> , 2017 , 49, 44-53	5.2	19
44	Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 928-35	3.1	22
43	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). <i>Lung Cancer</i> , 2016 , 93, 1-8	5.9	11
42	A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. <i>Radiotherapy and Oncology</i> , 2016 , 118, 369-74	5.3	24
41	Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , 2016 , 30, 279-86	2.5	9
40	An update on the randomized phase III POST trial: S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4042-4042	2.2	1

39	Patterns of recurrence by microsatellite instability in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 501-501	2.2	1
38	A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas. <i>Cancer Research and Treatment</i> , 2016 , 48, 409-14	5.2	3
37	Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after neoadjuvant chemoradiation therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 760-760	2.2	
36	Ipilimumab real-world efficacy and safety in Asian melanoma patients from the Korean Named-Patient Program cohort.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21002-e21002	2.2	
35	Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. <i>Oncotarget</i> , 2016 , 7, 44608-44620	3.3	31
34	Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors. <i>PLoS ONE</i> , 2016 , 11, e0161475	3.7	19
33	Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. <i>Annals of Surgery</i> , 2016 , 263, 96-102	7.8	43
32	Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. <i>British Journal of Cancer</i> , 2016 , 115, 25-33	8.7	87
31	Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. <i>Oncology</i> , 2015 , 88, 147-56	3.6	14
30	PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. <i>Oncology</i> , 2015 , 88, 76-85	3.6	24
29	A Randomized Phase 2 Study of Neoadjuvant Chemoradiation Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 1015-22	4	21
28	Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 224-31	3.1	38
27	Clinical implications from a single-center study of colorectal adenocarcinoma in transplant recipients. <i>Oncology</i> , 2015 , 88, 195-200	3.6	1
26	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , 2015 , 47, 781-9	5.2	7
25	Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15020-e15020	2.2	
24	A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 277-82	3.5	120
23	Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. <i>Tumor Biology</i> , 2014 , 35, 5735-40	2.9	26
22	Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2615-24	3.1	17

21	Retraction: Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. <i>Yonsei Med J</i> 2012;53:931-9. <i>Yonsei Medical Journal</i> , 2013 , 54, 269	3	
20	Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. <i>Yonsei Medical Journal</i> , 2013 , 54, 854-64	3	9
19	A randomized phase II study of neoadjuvant chemoradiotherapy with 5-FU/leucovorin or irinotecan/S1 in patients with locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 511-511	3.1	1
18	The effect of delay of adjuvant chemotherapy on survival in patients with resected stage II and III gastric cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15144-e15144	2.2	
17	Clinicopathologic features predicting HER2 overexpression in gastric cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15098-e15098	2.2	
16	Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. <i>BMC Cancer</i> , 2012 , 12, 471	4.8	1
15	EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. <i>Yonsei Medical Journal</i> , 2012 , 53, 1128-35	3	19
14	Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. <i>Yonsei Medical Journal</i> , 2012 , 53, 931-9	3	16
13	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. <i>Investigational New Drugs</i> , 2012 , 30, 1501-10	4.3	17
12	Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. <i>Oncology Letters</i> , 2012 , 3, 699-703	3.6	10
11	Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. <i>PLoS ONE</i> , 2012 , 7, e45127	3.7	13
10	Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14652-e14652	2.2	
9	Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 685-693	3.1	28
8	Brain metastases from colorectal carcinoma: prognostic factors and outcome. <i>Journal of Neuro-Oncology</i> , 2011 , 101, 49-55	4.8	65
7	Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity. <i>Oncology</i> , 2011 , 80, 107-17	3.6	10
6	MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. <i>Hepato-Gastroenterology</i> , 2011 , 58, 2015-9		24
5	Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. <i>Cancer Science</i> , 2010 , 101, 2200-6	6.9	19
4	Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients. <i>Oncology</i> , 2010 , 79, 293-300	3.6	12

3	The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. <i>Annals of Surgical Oncology</i> , 2010 , 17, 3259-68	3.1	38
2	The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 517-26	4.9	24
1	Prognosis of pN3 stage gastric cancer. <i>Cancer Research and Treatment</i> , 2009 , 41, 73-9	5.2	16